Scarica l'app Stockscreener
103.91
0.91%
0.94
Pre-mercato:
106.00
2.09
+2.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 Shares - MarketBeat
Axsome therapeutics’ general counsel sells $2.28 million in stock - Investing.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven? - Yahoo Finance
Axsome Therapeutics to Present SYMBRAVO® Clinical Data at the 67th Annual Scientific Meeting of the American Headache Society - Nasdaq
Prosperity Wealth Management Inc. Buys New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
SYMBRAVO Breakthrough: New Data Reveals Effectiveness in CGRP-Resistant Migraine Patients - Stock Titan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.33 Average Target Price from Analysts - MarketBeat
Axsome Therapeutics (AXSM) Supports Migraine Awareness and Commu - GuruFocus
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - The Manila Times
Axsome Therapeutics Partners With Migraine Association to Help 40 Million US Patients Find Better Days - Stock Titan
GAMMA Investing LLC Purchases 21,986 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Q3 EPS Forecast for Axsome Therapeutics Decreased by Analyst - MarketBeat
Royal Bank of Canada Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN
Rhumbline Advisers Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome fell after FDA refuses to review AXS-14 application - MSN
Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright - MarketBeat
Equities Analysts Issue Forecasts for AXSM FY2026 Earnings - MarketBeat
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market By Investing.com - Investing.com Nigeria
Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com
Assenagon Asset Management S.A. Purchases 623,717 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat
RBC Capital Adjusts Price Target for AXSM, Maintains Outperform - GuruFocus
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC - MarketBeat
Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00 - MarketBeat
Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital - GuruFocus
Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - MSN
RBC Capital Adjusts Price Target for AXSM, Maintains Outperform Rating | AXSM Stock News - GuruFocus
Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital | AXSM Stock News - GuruFocus
RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating - MarketScreener
Axsome Presents Positive Phase 3 Data for AXS-12 in Narcolepsy at SLEEP 2025 - HCPLive
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OSCR, AXSM and ET - ACCESS Newswire
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference - Nasdaq
Axsome Unveils Phase 3 Narcolepsy Trial Results Among 7 Major Presentations at SLEEP 2025 - Stock Titan
Transcript : Axsome Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener
Axsome Therapeutics, Inc. Announces Availability of Symbravo (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine with or Without Aura in Adults - marketscreener.com
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st
Axsome Therapeutics Launches SYMBRAVO for Migraine Relief - TipRanks
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating - marketscreener.com
Axsome Therapeutics (AXSM) Launches SYMBRAVO for Migraine Relief in the U.S. | AXSM Stock News - GuruFocus
Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways - Stock Titan
Axsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLC - Defense World
Axsome Therapeutics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada
Axsome’s fibromyalgia drug application hits FDA roadblock By Investing.com - Investing.com South Africa
Axsome Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AXSM - Benzinga
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):